Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Reports that Data from the Phase 2 Trimesta(TM) Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator

PR Newswire November 25, 2015

Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire November 24, 2015

A Look Inside the Chart, Technical Insights - Research on Tilly's, Geospace Technologies, Synthetic Biologics and TrovaGene

Accesswire November 20, 2015

Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City

PR Newswire November 19, 2015

Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights

PR Newswire November 5, 2015

Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)

PR Newswire October 21, 2015

Synthetic Biologics' Novel Irritable Bowel Syndrome with Constipation (IBS-C) Program Featured in American College of Gastroenterology Poster

PR Newswire October 20, 2015

Synthetic Biologics to Report Third Quarter Results on November 5, 2015

PR Newswire October 19, 2015

Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire October 8, 2015

Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing

PR Newswire October 1, 2015

Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial

PR Newswire September 28, 2015

Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability to Protect the Microbiome from Damage Caused by IV Antibiotics in a Humanized Pig Model

PR Newswire September 21, 2015

Synthetic Biologics Reports Second Quarter 2015 Financial Results and Operational Highlights

PR Newswire August 10, 2015

Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria

PR Newswire August 10, 2015

Synthetic Biologics to Report Second Quarter Results on August 10, 2015

PR Newswire July 29, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

Synthetic Biologics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option

PR Newswire July 21, 2015

Synthetic Biologics Announces Pricing of $40.0 Million Public Offering

PR Newswire July 16, 2015

Synthetic Biologics Announces Public Offering of Common Stock

PR Newswire July 15, 2015